Blue Water Biotech Acquires Six FDA-Approved Drugs From WraSer For $8.5M Cash Consideration And 1M Restricted Shares
Portfolio Pulse from Benzinga Newsdesk
Blue Water Biotech has acquired six FDA-approved drugs from WraSer for $8.5 million in cash and 1 million restricted shares. The deal expands Blue Water's product portfolio and strengthens its position in the pharmaceutical market.
June 14, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blue Water Biotech's acquisition of six FDA-approved drugs from WraSer for $8.5M cash and 1M restricted shares could boost its stock price in the short term.
The acquisition of six FDA-approved drugs from WraSer expands Blue Water Biotech's product portfolio and strengthens its position in the pharmaceutical market. This could lead to increased revenues and profitability, which may positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100